You are here

Symposium Speaker biographies

Florian Lordick
University Hospital Leipzig
Leipzig, Germany
 

Florian Lordick, MD, PhD, is Professor of Oncology and Director of the University Cancer Centre Leipzig (UCCL) at the University Hospital Leipzig in Germany. Professor Lordick completed his medical training at the universities of Regensburg and Munich in Germany, and Lausanne in Switzerland. He gained board certifications in internal medicine, haematology, and medical oncology, and in 2002 he was appointed consultant physician at the Technical University of Munich. In July 2007 he was nominated Assistant Professor and Head of the Outpatient Department at the National Centre for Tumour Diseases, University of Heidelberg, Germany; in 2009 he was appointed Head of Haematology and Oncology at the Klinikum Braunschweig in Braunschweig, Germany, and Associate Professor at Hannover Medical School in Hannover, Germany. He took up his current posts as Full Professor at the University of Leipzig and Director of the UCCL in 2012.

Professor Lordick is a member of the Board of Directors of the German Cancer Society (DKG) and Secretary of the European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Group (EORTC-GITCG). In 2015 he was elected as incoming President of the International Gastric Cancer Association (IGCA) and as Congress Chair of the 2019 International Gastric Cancer Congress, to be held in Prague.

Professor Lordick’s scientific focus is on clinical and translational research in gastrointestinal cancer, the optimization of multimodal care, new drug development, molecular imaging, and response prediction. He has authored or co-authored more than 200 articles on gastrointestinal cancer; he is co-editor of a number of important international oncology journals and a reviewer for international and national research and funding societies.
 

Romano Danesi
University Hospital of Pisa
Pisa, Italy


Romano Danesi, MD, PhD, is Professor of Pharmacology at the University of Pisa School of Medicine, and Director of the Clinical Pharmacology and Pharmacogenetics Unit at the University Hospital of Pisa, Italy. Professor Danesi earned his MD degree at the University of Pisa in 1983 and his PhD in 1988; he then gained board certification in pulmonary diseases, clinical pharmacology, and medical oncology. He was appointed Adjunct Professor of Clinical Pharmacology at the University of Pisa School of Medicine in 1990, then took up the post of Assistant Professor of Pharmacology in 1991. Professor Danesi spent 4 years working as a Visiting Fellow at the National Cancer Institute, NIH, Bethesda, MD, and as Assistant Professor of Hematology/Oncology at the University of Virginia Health Sciences Center in Charlottesville, VA, USA. He was appointed Associate Professor of Pharmacology at the University of Pisa School of Medicine in 1998 and Full Professor in 2005.

Professor Danesi’s scientific work focuses on pharmacogenomic, proteomic, and drug analysis approaches for personalized treatment in oncology. He has worked as an independent expert evaluator and rapporteur of research proposals within the FP6, FP7, and Horizon 2020 framework programmes of the European Commission. He is also Chair of the Ethics Committee and Independent Review Board for the University Hospital of Pisa. He has authored or co-authored more than 300 articles in peer-reviewed journals including Cancer Treatment Reviews, Clinical Colorectal Cancer, Pharmacological Reviews, and Clinical Pharmacokinetics, and has an h-index of 42.
 

Hansjochen Wilke
Essen-Mitte Hospital
Essen, Germany
 

Hansjochen Wilke, MD, PhD, is Medical Director of the Essen-Mitte Hospital in Essen, Germany, and Head of the Department of Internal Medicine and Oncology/Haematology at the same hospital. He has held these posts since 2004 and 1999, respectively. After earning his MD degree in 1979, Professor Wilke worked in the Department of Medicine at the University of Würzburg in Germany, becoming a fellow in the haematology/oncology section in 1982. He was Assistant Medical Director and Assistant Professor of Internal Medicine at the Hannover University Medical

School in Hannover, Germany, from 1985 to 1990; Assistant Medical Director of the Department of Internal Medicine (Cancer Research) at the West German Cancer Centre, Essen, and Associate Professor of Internal Medicine at the University Medical School, Essen, from 1991 to 1996; and Head of the Department of Oncology at the Essen-Mitte Hospital from 1996 to 1999.

Professor Wilke’s main fields of clinical research are gastrointestinal tract cancer, lung cancer, breast cancer, and combined modality treatments; his main fields of experimental research are the timing and scheduling of drugs and drug combinations in vitro (cell culture) and in vivo (hetero-transplanted xenografts) and drug resistance in vitro and in vivo.

Professor Wilke is a member of many professional organizations, including the European Society for Medical Oncology (ESMO); the American Society of Clinical Oncology (ASCO); the International Society of Gastric Cancer (ISGC); and the European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Group (EORTC-GITCG). He has published widely in peer-reviewed journals  including The Lancet Oncology, Journal of Clinical Oncology, Annals of Oncology, and Anticancer Drugs.


Ian Chau
Royal Marsden Hospital and Institute of Cancer Research
Sutton, UK
 

Ian Chau, MD, FRCP, holds the position of Consultant Medical Oncologist within the Gastrointestinal and Lymphoma Units at the Royal Marsden Hospital, Sutton, and is an honorary senior lecturer at the Institute of Cancer Research in London and Sutton, UK. Dr Chau qualified with an MD degree from the United Medical and Dental Schools of Guy’s and St Thomas’ Hospitals, University of London, UK, before completing medical oncology specialist training and taking up a clinical research fellowship at the Royal Marsden Hospital.

Dr Chau’s main research interests are in clinical trials and translational research in gastrointestinal cancers and lymphoma. He is the chief or principal investigator of multiple phase 1, 2, and 3 clinical trials evaluating novel treatment strategies and agents in various cancer signalling pathways. He serves or has served on the American Society of Clinical Oncology (ASCO) Scientific Program Committee, the European Society of Medical Oncology (ESMO) Congress Steering Committee, the ESMO Educational Committee, and the UK National Cancer Research Institute (NCRI) Colorectal Cancer and Pancreatic Cancer Clinical Study Groups. He is a member of the trial management groups and trial steering groups of multiple national and global phase 2 and 3 gastrointestinal cancer and lymphoma trials.

Dr Chau has given invited lectures in more than 30 countries. He has served on international drug development advisory boards and has published in peer-reviewed journals including the New England Journal of Medicine, The Lancet, The Lancet Oncology, Journal of Clinical Oncology, and other leading oncology/biomedical journals.


Luigi Bolondi
Bologna University Hospital S. Orsola Malpighi
Bologna, Italy
 

Luigi Bolondi, MD, is Professor of Internal Medicine at the Bologna University Hospital S. Orsola Malpighi in Bologna, Italy, and has been Director of the Division of Internal Medicine at the same hospital since 1997. He founded the Centre for Applied Medical Research at Bologna University Hospital S. Orsola Malpighi in 2001, and was director of this centre until 2014. In 2012 he became Dean of the School of Medicine and Surgery of the University of Bologna.

Professor Bolondi’s research activities have concentrated chiefly on the pathophysiology, diagnosis, and treatment of liver diseases. He pioneered the development of the application of ultrasound in medicine during the 1970s, and founded the Italian Society for Ultrasound in Medicine and Biology (SIUMB), serving as its General Secretary and then President, and was President of the European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB) from 1996 to 1999. He was a member of the scientific board of the Italian Association for the Study of the Liver (AISF) from 1993 to 1996, and is an honorary member of the American Institute of Ultrasound in Medicine (AIUM).

Professor Bolondi has organized and been president of many national and international congresses, including the World Congress of Ultrasound in Medicine and Biology in 2000 and the European Congress for Ultrasound in Medicine and Biology in 2006. He was a member of the editorial board of Hepatology and is currently a member of the editorial board of the Journal of Clinical Ultrasound and an associate editor of the Journal of Hepatology. He has published more than 300 papers in international journals with a total impact factor of more than 1,600 and has an h-index of 54.


Search this site

Search form

ECCO2017 Symposium

Joining a conversation on the treatment evolution in advanced GI malignancies: yesterday, today, and tomorrow

Official Sponsored Satellite Symposium at ECCO 2017: European Cancer Congress, 29 January 18:45 – 20:15

E-Alert

Subscribe to our E-Alert to keep up to date with the new items in the Resource Centre

Featured Content

New Book Content


This online Resource Centre has been sponsored by Lilly Oncology

Note that Lilly Oncology has no editorial control over the content of this Resource Centre. The Resource Centre and all content therein has been subject to an independent editorial review.

Share